Rigel Pharmaceuticals: Significant Revenue and Profit Increase in Q3 Excites H.C. Wainwright Analysts

Rigel Pharmaceuticals (RIGL) positions itself as a biotechnology company focused on hematological disorders and cancer. The company is already commercially active and currently offers three approved products that represent the core solutions for its customers, namely treating physicians and patients: TAVALISSE (Fostamatinib) is used for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatment. In ITP, the immune system attacks the body's own platelets,...